To ensure quality, safety and efficacy, regulatory health authorities worldwide require new medical therapies to be tested on animals before they are tested on humans. As we continue expanding the frontiers of sight-saving and vision-restoring products and services, Alcon has a responsibility to comply with these regulations.
The welfare of animals in our care is of primary concern to us for reasons of ethics, accuracy, reliability and applicability of scientific studies. Good animal welfare is a prerequisite for good science, as reducing the stress levels in animals improves the quality of our scientific results. Alcon is committed to achieving high standards of animal welfare whenever animals under our care are involved in research studies.
Replace tests with non-animal testing methods wherever possible and appropriate.
Reduce the number of animals used in each study.
Refine testing to use the least invasive and painful methods feasible.
Respect is Alcon’s own addition to this global standard. We believe it is vital to respect the inherent integrity of the animal and its contribution to our research.
Animal Welfare Policy
Alcon follows the Novartis Animal Welfare Policy, which sets out the principles that govern our approach to animal welfare – principles that frequently exceed the requirements of local regulations. Read the Novartis Animal Welfare Policy.
An Exemplary Record
We ensure the ethical treatment of any animals used for testing in our facilities:
All research requiring animal testing is subject to the approval of, and monitoring by, a committee of veterinarians, scientists and independent, third-party community members.
Alcon consistently receives exemplary ratings and commendations on the conditions of our facility, quality of animal care and overall animal health. These are based on unannounced inspections performed by veterinarians from the U.S. Department of Agriculture (USDA) in accordance with the Animal Welfare Act.
We support initiatives that reduce the necessity of animal testing, such as the international harmonization of toxicity. Introduced by the International Conference on Harmonization (ICH), this proposition reduced the requirement of three similar tests needed for product approval in the U.S., Japan and the EU to just one.